Agilent investing $725 million to expand state-of-the-art manufacturing capacity for production of nucleic acid-based therapeutics

Santa clara, calif.--( business wire )--agilent technologies inc. (nyse: a) today announced it is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market and strong demand for the company's high-quality active pharmaceutical ingredients (api).
A Ratings Summary
A Quant Ranking